Search Results - aplastic+anemia

4 Results

Sort By:

The invention hereby offered for licensing is in the field of Immunotherapy and more specifically in therapy of autoimmune diseases such as Type I diabetes, multiple sclerosis, rheumatoid arthritis and systemic lupus erythematosis and immune mediated allergies such as asthma as well as in transplantation-related disorders, such as graft acceptance...

Published: 7/25/2024 | Inventor(s): Ethan Shevach, Dat Tran

Keywords(s): 2, ACTIVATED, ALLOWS, Aplastic anemia, Aplastic anemia, idiopathic; Aplastic anemia, Associated, CD121b, CELL-BASED, Cells, CULTURES, EXPANSION, Expression, FOXP3+, Generate, Graft versus host disease, Human, IB3XXX, IBXXXX, Idiopathic thrombocytopenic purpura, IL-l, Immunotherapy, IXXXXX, LAP, Latency, NUMBERS, Patent Category - Biotechnology, Peptide, purification, RECEPTOR, Regulatory, SELECTIVE, Sufficient, Systemic lupus erythematosus, T, Their, Thrombocytopenic purpura, autoimmune, TYPE

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Immunology, Application > Diagnostics, Application > Research Materials

Methods for Expression and Purification of Immunotoxins

The invention concerns immunotoxins and methods of making the immunotoxins. Targeting of the immunotoxins occurs via an antibody that is specific to T cells. This allows the specific ablation of malignant T cells and resting T cells. The transient ablation of resting T cells can "reset" the immune system by accentuating tolerizing responses. As...

Published: 7/25/2024 | Inventor(s): David Neville

Keywords(s): Aplastic anemia, Are, Bivalent, CB6XXX, CBXXXX, COMPLEX, CXXXXX, ESSENTIAL, Graft versus host disease, IB3XXX, IBXXXX, Immunotoxin, IXXXXX, LOW, lymphoma, Media, PASTORIS, PICHIA, production, temperature

Category(s): Collaboration Sought > Licensing, Application > Research Materials, TherapeuticArea > Immunology, Application > Diagnostics, Application > Therapeutics, TherapeuticArea > Oncology

Immunotoxin with in-vivo T cell Suppressant Activity

The invention concerns immunotoxins and methods of using the immunotoxins for the treatment of autoimmune diseases and T cell malignancies. The immunotoxins are targeted via an antibody that is specific to T cells. This allows the specific ablation of malignant T cells and resting T cells. The transient ablation of resting T cells can "reset" the...

Published: 7/25/2024 | Inventor(s): David Neville

Keywords(s): Activity, Aplastic anemia, CB1XXX, CBXXXX, Cell, CXXXXX, IB3XXX, IBXXXX, IMMUNE, Immunotoxin, IMMUNOTOXINS, INDUCING, IN-VIVO, IXXXXX, lymphoma, Methods, Novel, SUPPRESSANT, T, TOLERANCE, UAXXXX, Vivo

Category(s): Collaboration Sought > Licensing, TherapeuticArea > Oncology, TherapeuticArea > Immunology, TherapeuticArea > Rare / Neglected Diseases, Application > Diagnostics, Application > Research Materials, Application > Therapeutics

TTP as a Regulator of GM-CSF mRNA Deadenylation and Stability

The disclosed invention provides materials and methods to treat granulocytopenia (low white cell count in the blood) which is characterized by a reduced number of granulocytes (relative) or an absence of granulocytes (absolute). This condition is commonly associated with cancer chemotherapy, but is seen less frequently in a number of conditions including...

Published: 7/25/2024 | Inventor(s): Wi Lai, Perry Blackshear, Ester Carballo

Keywords(s): Aplastic anemia, Deadenylation, Duke DNA Project, GM-CSF, Granulocytopenia, IB6XXX, IBXXXX, IXXXXX, REGULATOR, STABILITY, Systemic lupus erythematosus, TTP, UA1XXX

Category(s): Collaboration Sought > Licensing, Collaboration Sought > Materials Available, TherapeuticArea > Reproductive Health, Application > Research Materials, Application > Diagnostics, Application > Therapeutics, Application > Vaccines, TherapeuticArea > Rare / Neglected Diseases